https://www.selleckchem.com/pr....oducts/itacitinib-in
In multivariate analysis, Group 3, but not Groups 2 and 4, had an increased risk of poor 3- and 12-month functional outcome (adjusted OR 2.59, 95% CI 1.64-4.07, P 0.01 and OR 3.97, 95% CI 2.32-6.76, P 0.01, respectively) compared with Group 1. Different trajectories of post-stroke DS are related to different outcomes. Patients who only have later DS also have the worst prognosis. Different trajectories of post-stroke DS are related to different outcomes. Patients who only have later DS also have the worst prognosi
Beğen
Yorum Yap
Paylaş
